Setup

Prime Medicine (PRME) filed an 8-K on April 16 disclosing a new CFO, Svetlana Makhni, with Goldman Sachs / Blackstone / BMO Capital Markets advisory background and three prior clinical-stage biotech CFO seats. The March 3, 2026 10-K carried a formal going-concern disclosure confirmed by EY: $177.7M cash, $162.6M FY2025 burn, a $300M ATM shelf with zero drawn. The hire is the organizational preamble to a capital event. The question is on what terms, paired with which catalyst, and whether existing positioning already prices the outcome. Our read: largely yes.

What the filing says

Item 5.02, single item. Makhni appointed CFO effective April 16, 2026. CEO Allan Reine had been serving as principal financial officer; that dual role ends.

Compensation: $495K base, 40% target bonus, $40K sign-on (repayable on voluntary departure within 12 months), 800K time-based options (1-year cliff, 36-month monthly thereafter), 100K milestone-based options with milestones set by the CEO. CIC double-trigger: 12 months base plus full time-based acceleration.

Background: BMO / Goldman / Blackstone (2006-2019) advising equity, debt, and M&A. Biotech CFO at Marengo Therapeutics (2022-April 2026), Escient, Bierman ABA. Harvard MBA, Wharton undergrad.

No prior 8-K announced a CFO departure; the length of the dual-hat period is not disclosed.

What the market thinks

Market cap ≈$0.7B. 52-week range $1.11–$6.94; currently at 44% of range.

Options read strongly bullish: P/C OI 0.15, ATM IV 107% (50th percentile of trailing year), max pain $4.00, call wall at $5 (2,539 OI), IV skew +63% toward OTM calls. Nearest expiry May 15 sits before the expected Wilson IND window.

Analyst consensus: 9 Buy, 4 Hold, 0 Sell. Mean target $6.92 (+88%), median $6.00 (+63%). Oppenheimer upgraded Outperform with an $11 target on March 12, 2026 — after the ARCH accumulation, not before.

Insider buying is verified Tier-1. ARCH Venture Partners (Nelsen) and Google Ventures jointly bought $15M at $3.30 on August 1, 2025. Founder-scientist David Liu (inventor of prime editing) bought four tranches in June 2025 at $1.49-$3.24. CEO Reine and two officers added $284K at $1.13-$1.18 in May 2025.

Short interest 19.7% of float, 9.1 days to cover.

Our probability-weighted 12-month EV works out to a range of roughly +15-30% (Sharpe ≈0.2) against the analyst median implying closer to +60%. 90-day EV is mildly negative because the dilution overhang from the expected raise outweighs the Wilson IND catalyst in that window.

Why the gap exists

Primarily, it doesn't. ARCH/GV $15M at $3.30, founder-scientist buying at deeper lows, officer buying at $1.13, an IB-pedigreed transaction CFO arriving 13 months from cash zero, call skew +63% OTM, an Oppenheimer $11 chase target — the convergent signal is visible to anyone who looks.

What is less fully priced:

1. The probability weights. Analyst targets ($6-11) imply meaningful mass on a state where Wilson and AATD INDs file on time, Phase 1 preliminary data is positive, BEAM resolves favorably, and a partnership lands. We assign that conjunction roughly 15%. Bear states — dilution overhang, BEAM adverse, going-concern escalation — carry about 50% combined weight in our decomposition. The spread is where the analyst-vs-our-EV gap lives.

2. The order of operations. Whether the Wilson IND 8-K precedes or follows the capital raise materially changes entry economics. Clinical catalyst paired with a raise at favorable terms compresses the state-B case upward; a raise announced first at a discount does the opposite. May 7 earnings should narrow "1H 2026" to a specific week.

3. BEAM arbitration legal merits. PM647's pegRNA design and editing mechanism (transition vs transversion) is not publicly disclosed. BEAM's Feb 2026 10-K still calls it "not material." Either characterization will prove wrong, and the resolution is asymmetric. This is our longest-standing open gap.

The honest frame: the edge available here is reflexive more than predictive. The market priced the insider-signal tier through options positioning and sell-side upgrades before we graded it. The memo's value, if any, is decomposing the EV against analyst consensus rather than surfacing a hidden fact.

Risks

1. Going-concern tail. Cash exhausts approximately Q1-Q2 2027 at current burn; burn rises as Phase 1/2 trials initiate. Emergency financing at distressed terms = -60 to -80% scenario, 10-15% probability weight.
2. BEAM arbitration adverse ruling. Trade secret and business tort claims added; AATD field exclusivity at stake. Adverse = -40 to -50%.
3. Dilution execution. Shares outstanding ≈180M. Pending internal prediction: 85% probability shares exceed 220M by Dec 31, 2026. Raise at >25% discount = mechanical -15 to -30%.
4. IND slippage. Either Wilson or AATD delaying into H2 2026 compresses runway and forces worse raise terms.
5. XBI regime. Beta 2.67, idiosyncratic volatility ≈105%. Small-cap biotech risk-off bleeds PRME independently of fundamentals.

Catalysts

• May 7, 2026 — Q1 earnings. Burn rate, runway update, Wilson IND timing precision within Q2.
• By June 30, 2026 — Wilson Disease (PM577) IND/CTA filing (internal 75%).
• By July 15, 2026 — Capital transaction announcement (internal 55%).
• Mid-2026 — AATD (PM647) IND, subject to BEAM arbitration.
• Undated — BEAM arbitration resolution; CGD (PM359) partnership, flagged in 10-K as strategic-alternatives candidate.
• By Dec 31, 2026 — Capital raise completed (internal 95%); shares >220M (internal 85%).

What would change our mind

• Bullish: Wilson IND filing AND partnership or non-dilutive structured-deal 8-K within 60 days → upper-tail probability rises, 12-month EV reprices up ≈10pts.
• Bullish: Q1 earnings burn <$35M/quarter → runway extends to mid-2027, urgency premium compresses.
• Bullish structural: PM647 pegRNA mechanism disclosed in patent or publication and shown non-transition → BEAM overhang mechanically dissolves.
• Bearish: Q1 earnings burn >$45M/quarter → runway compresses to late 2026, emergency-financing scenario rises to ≈25%.
• Bearish: 8-K announcing ATM draw at >15% discount → punitive dilution materializes.
• Neutralizing: BEAM arbitration resolution (either direction) → compresses variance on the largest bear tail.

Evidence

The May-August 2025 insider purchases (ARCH/GV, Liu, officers) are not independent signals — they cluster around the same accumulation pattern at the same price trough. Weight accordingly.

Memo LR: 1.1